Dry Age Macular Degeneration Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Linea

DelveInsight's "Dry Age Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Dry Age Macular Degeneration, historical and forecasted epidemiology as well as the Dry Age Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Dry Age Macular Degeneration Market Share @ Dry Age Macular Degeneration Market Outlook- https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Dry Age Macular Degeneration Market Report
• In April 2025, Stealth Bio Therapeutics Inc., a clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections.
• In April 2025, Hoffmann-La Roche conducted a study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
• In February 2025, Luxa Biotechnology announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to its RPESC-RPE-4W transplantation for treating dry age-related macular degeneration (dry AMD). Luxa is developing this novel adult retinal pigment epithelial stem cell therapy for dry AMD patients.
• The total prevalent cases of AMD in the 7MM was nearly 68,347,900 in 2023.
• Among the 7MM, the US accounted for the highest prevalent cases of dry AMD in 2023, with around 20,970,000 cases; these cases are expected to increase during the forecast period.
• Several researchers reported a declining prevalence of late AMD in the United States when comparing data from the 2000s with data gathered in previous decades.
• In 2023, the geographical atrophy accounted for nearly 955,900 cases in EU4 and the UK.
• According to the estimates, in Japan, it is observed that age-specific cases of geographic atrophy were most prevalent in the 85+ years age group, accounting for over 40% of total cases in 2023.
• Although there are relatively equal numbers of neovascular AMD and geographic atrophy in White populations, late AMD is less common among Japanese people than among white subjects. In Asian countries, although the prevalence of geographic atrophy is low, the rapidly aging population means that geographic atrophy is becoming an increasingly urgent and unmet medical need. The difference in the prevalence of AMD among races is also partly owing to genetic background; for example, some single nucleotide polymorphisms (SNPs) in complement factors are associated with AMD in Caucasians.
• The increase in Dry Age Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Dry Age Macular Degeneration Market is anticipated to witness growth at a considerable CAGR.
• The leading Dry Age Macular Degeneration Companies such as Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Evergreen Therapeutics, Annexon Biosciences, NGM Biopharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Regenerative Patch Technologies and others.
• Promising Dry Age Macular Degeneration Pipeline Therapies such as QA102, Risuteganib, MA09-hRPE, unoprostone isopropyl, Elamipretide, OpRegen, Metformin, and others.

Stay ahead in the Dry Age Macular Degeneration Therapeutics Market with DelveInsight's Strategic Report @ Dry Age Macular Degeneration Market Outlook- https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Age Macular Degeneration Epidemiology Segmentation in the 7MM
The epidemiology section of Dry Age Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Total prevalent cases of AMD
• Stage-specific prevalent cases of AMD
• Total prevalent cases of geographic atrophy
• Total prevalent cases of dry AMD
• Total diagnosed prevalent cases of dry AMD
• Age-specific cases of early and intermediate AMD
• Age-specific cases of geographic atrophy

Download the report to understand which factors are driving Dry Age Macular Degeneration Epidemiology trends @ Dry Age Macular Degeneration Prevalence- https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Age-related Macular Degeneration Marketed Drugs
• IZERVAY (avacincaptad pegol): Astellas Pharma/Iveric Bio
IZERVAY, also known as avacincaptad pegol is designed to target and inhibit complement factor C5. Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of dry AMD. IZERVAY binds to C5 and inhibits its cleavage into the terminal fragments C5a and C5b. By inhibiting the formation of complement system terminal fragments, IZERVAY may decrease the activation of inflammasomes and the formation of membrane attack complexes (MAC), which occur at the end of the complement cascade. In August 2023, the US FDA approved IZERVAY for the treatment of geographic atrophy secondary to AMD. Concurrently, Astellas Pharma announced that the European Medicines Agency (EMA) has accepted Iveric Bio's MAA for avacincaptad pegol for the treatment of geographic atrophy secondary to AMD.

• SYFOVRE (pegcetacoplan): Apellis Pharmaceuticals
SYFOVRE is a targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is a type of synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. The company is evaluating pegcetacoplan in several clinical studies, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), warm antibody autoimmune hemolytic anemia (wAIHA), complement-dependent nephropathies (CDN). SYFOVRE is the first and only approved therapy for geographic atrophy secondary to AMD. In January 2024, the CHMP of the EMA adopted a negative opinion on the MAA of intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to AMD.

Dry Age-related Macular Degeneration Emerging Drugs
• Iptacopan (LNP023): Novartis
Novartis Pharmaceuticals is developing Iptacopan, an oral small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, FB inhibitor LNP023 binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as intermediate age-related macular degeneration (iAMD), C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), etc. Recently, in December 2023, the US FDA approved FABHALTA (ipatocan) as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH) (Novartis, 2023). Currently, the company is investigating iptacopan in the Phase II trial (NCT05230537) for the treatment of patients with early and intermediate age-related macular degeneration.

• ALK-001: Alkeus Pharmaceuticals
Allegro Ophthalmics is developing risuteganib (also known as ALG-1001), a breakthrough integrin-regulating therapy for ocular health that reduces mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib helps reduce the cellular burden of oxidative stress and restores retinal homeostasis. Research suggests that risuteganib interferes with integrin functions that have been implicated in retinal diseases, giving it the potential for a broad-spectrum effect on different pathways of oxidative stress. Currently, the company has received the US FDA agreement under Special Protocol Assessment (SPA) for Phase IIb/III clinical trial of risuteganib for the treatment of intermediate, non-exudative age-related macular degeneration (dry AMD). Moreover, the overall protocol design of Phase IIb/III dry AMD clinical trial was finalized by the US FDA.

To learn more about Dry Age Macular Degeneration treatment guidelines, visit @ Dry Age Macular Degeneration Treatment Market Landscape- https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Dry Age Macular Degeneration Market Outlook
Geographic atrophy, the advanced stage of dry AMD, has emerged as a prominent focus of research. Current investigations predominantly center on therapies targeting complement inhibitors of C3 and C5, pivotal factors in triggering inflammation and subsequent cell death within the eye. Extensive studies led by the National Eye Institute and esteemed researchers globally have unveiled the likelihood of an overactive complement system as a central player in the genesis of dry AMD and its evolution toward GA.

Dry Age Macular Degeneration Drugs Uptake
The drug chapter of the Dry Age Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Dry Age Macular Degeneration.

Major Dry Age Macular Degeneration Companies
Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Evergreen Therapeutics, Annexon Biosciences, NGM Biopharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Regenerative Patch Technologies and others

Learn more about the FDA-approved drugs for Dry Age Macular Degeneration @ Drugs for Dry Age Macular Degeneration Treatment- https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Dry Age Macular Degeneration Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Dry Age Macular Degeneration Companies-Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Evergreen Therapeutics, Annexon Biosciences, NGM Biopharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Ionis Pharmaceuticals, Novartis, Regenerative Patch Technologies and others
• Dry Age Macular Degeneration Pipeline Therapies- QA102, Risuteganib, MA09-hRPE, unoprostone isopropyl, Elamipretide, OpRegen, Metformin, and others.
• Dry Age Macular Degeneration Market Dynamics: Dry Age Macular Degeneration Market Drivers and Barriers
• Dry Age Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Dry Age Macular Degeneration Drugs in development @ Dry Age Macular Degeneration Clinical Trials Assessment- https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Dry AMD
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Dry AMD Market Overview at a Glance
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. Dry AMD: Market Analysis
13. Unmet Needs
14. SWOT Analysis
15. KOL Views
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Psoriasis Vulgaris Market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Urea Cycle Disorders Market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Immune Checkpoints Activators Market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Cystic Fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Diabetic Wound Market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Overactive Bladder Syndrome Market- https://www.delveinsight.com/report-store/underactive-bladder-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Intraocular Lens Market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/blog/cardiac-monitoring-devices-market
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.